Variable | RRP (N = 97) | HDR (N = 161) | Cryo (N = 114) | HIFU (N = 120) | P value |
---|---|---|---|---|---|
Follow-up duration, months (mean ± SD) | 34.68 ± 12.45 | 33.54 ± 14.95 | 33.46 ± 14.38 | 32.68 ± 11.87 | 0.338 |
PSA nadir, ng/mL (mean ± SD) | 0.40 ± 1.10 | 0.94 ± 1.59 | 0.81 ± 2.29 | 0.64 ± 1.77 | 0.031 |
PSA biochemical recurrence, N (%) | 47 (48.5) | 88 (54.7) | 36 (31.6) | 29 (24.2) | 0.000 |
Low risk, N (%) | 2 (22.2) | 1 (16.7) | 2 (10.5) | 1 (6.7) | 0.699 |
Intermediate risk, N (%) | 3 (30.0) | 11 (34.4) | 3 (12.5) | 4 (8.5) | 0.020 |
High risk, N (%) | 42 (53.8) | 76 (61.8) | 31 (43.7) | 24 (41.4) | 0.024 |
PSA biochemical recurrence-free survival, months (mean ± SD) | 22.13 ± 14.85 | 21.17 ± 14.49 | 26.39 ± 12.53 | 27.66 ± 13.72 | 0.000 |
Salvage treatment free, N (%) | 59 (60.8) | 75 (46.7) | 82 (71.9) | 84 (70.0) | 0.000 |
Metastasis free, N (%) | 92 (94.8) | 146 (90.7) | 113 (99.1) | 119 (99.2) | 0.001 |